Real-World Betaseron Outcomes Study (ROBUST): A Twelve-month, US Prospective, Observational, Open-label, Single-arm, Multi-center Outcomes Study of Interferon beta-1b (Betaseron) Given Every Other Day for Relapsing Forms of Multiple Sclerosis.

Trial Profile

Real-World Betaseron Outcomes Study (ROBUST): A Twelve-month, US Prospective, Observational, Open-label, Single-arm, Multi-center Outcomes Study of Interferon beta-1b (Betaseron) Given Every Other Day for Relapsing Forms of Multiple Sclerosis.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Jul 2010

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms ROBUST
  • Sponsors Bayer
  • Most Recent Events

    • 07 Jul 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 07 Jul 2010 Official Title added as reported by ClinicalTrials.gov.
    • 07 Jul 2010 Planned end date (Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top